Want to join the conversation?
$ABBV said Stemcentrx has a broad development program for Rova-T currently underway. The confirmatory third-line trial which is called Trinity began in January and is expected to complete enrollment by the end of 2016 with commercialization expected in 2018. Stemcentrx is also moving into front-line, small cell lung cancer with Rova-T.
Wow! $MCD scores again.
$SPY can the rally continue? La Pen almost assured to lose makes me cautious about the results, not a place to panic. If 2400 is reached I'm selling my puts and going for broke. Happy hunting.
Trivago N.V. (TRVG) announced today that it will release its financial results for the first quarter for the period ended March 31, 2017 on Monday, May 15, 2017. On the same day, trivago N.V.`s management will conduct a webcast beginning at 2:00 PM CET / 8:00 AM Eastern Time. These items will be available in the Investor Relations section of the company`s website at http://ir.trivago.com.